Initial exploratory observational pharmacology of Valeriana wallichii on stress management: A clinical report

Dipankar Bhattacharyya,1 Utpalendu Jana,2 Pratip Kumar Debnath2 and Tapas Kumar Sur1

1Department of Pharmacology, Institute of Post Graduate Medical Education and Research, Kolkata, India
2JB Roy State Ayurvedic Medical College and Hospital, Kolkata, India

ABSTRACT

Valeriana wallichii, an Indian medicinal plant, has been on trial for its role in stress disorders in hospital based clinical set-up. Hamilton’s Brief Psychiatric Rating Scale (BPRS) was used and thorough clinical investigations were carried out to screen the subjects. Thirty-three subjects (20 male and 13 female; average age 34.2 years) were medicated with the plant extract in a fixed dose regime (500 mg/capsule, twice daily, p.o. after meal). They were thoroughly investigated clinically and using standard questionnaires based on different psychological rating scale at baseline (day 0), mid-term (day 30) and final (day 60). The observations exhibited that, V. wallichii not only significantly (p<0.001) attenuated stress and anxiety, but also significantly (p<0.001) improved depression and also enhanced the willingness to adjustment. Nevertheless it did not alter memory, concentration or attention of the volunteers. The results suggest that V. wallichii may be useful in the treatment of stress related disorders in human and may be a promising anti-stress agent in near future.

Keywords: Anxiety, stress, depression, adjustment, memory, valeriana wallichii.

INTRODUCTION

Anxiety or stress is a cardinal symptom of many psychiatric disorders and an almost inevitable component of many medicinal and surgical conditions. Symptoms of anxiety commonly associated with dysthymic disorder, panic disorder, agoraphobia, obsessive-compulsive disorder, eating disorder and many personalities disorders, while, with lifetime morbidity risk of over 10.0% in the general population, major depression is one of the most common mental illnesses.1,2 Throughout human history there have been searches for antidotes for the symptoms of anxiety and stress. In the late 1950s, the benzodiazepines were discovered, and have been widely used. Since the development of the first benzodiazepine, more than 2,000 related compounds have been synthesized, but few of them have been found to be clinically useful.3 This provides impetus in the search for newer and more effective anti-stress drugs. Natural products have played a significant role in the management of neuropsychiatric disorders.

Ayurveda, Indian system of traditional medicine has described CNS-activity under different categories. A number of medicinal plants from India have been shown to have activity by the traditional methods of psychopharmacology, Valeriana wallichii is one of them.4 Indian medicinal plant, V. wallichii (VW), a natural source of the sedative and tranquilizing valepotriates, is well documented.5 Valepotriates are responsible for the sedative action of the plant.6 Different in vitro cultures of valerianaceae were analyzed for valepotriate content. Using TLC and HPLC, twelve valepotriates has been isolated and identified by Proton Mass Resonance (PMR), Citron Mass Resonance (CMR) and Mass Resonance (MS). The rhizomes contained significantly higher levels of valepotriates than the roots.7-10 Valeriana belongs to the principal remedies in insomnia especially due to nervous exhaustion and mental overwork.11,12 Although the plant has been in traditional use for thousands of years in India, but till date there is no evidence-based clinical report. In this context, we aimed to investigate the Indian medicinal plant, V. wallichii for its role in mental disorders specially stress related disorders in human.

MATERIALS AND METHODS

The rhizomes of the V. wallichii were collected and identified from the Botanical Survey of India, West Bengal. Then they were washed, dried and made into fine powder. This powder was soaked in 70.0% ethanol. After 24 h at room temperature, the materials were filtered under vacuum. This process of extraction was further repeated for three times. The combined alcoholic extract of the plant was concentrated under reduced pressure in a rotary evaporator. The concentrated material was then lyophilized and the ultimate product was filled in gelatin capsules.13
The programmed clinical trail was done in the Out-Patient Clinics of the J. B. Roy State Ayurvedic Medical College and Hospital, Kolkata, India from the year 2001-2004. The trial was conducted in accordance with good clinical practice guidelines and conforming to the declaration of Helsinki, following approval by the Institutional Ethics Committee.

Patients of both sexes, of age group 18-60 years, suffering from Anxiety-Stress-Disorder, diagnosed during initial observation underwent detailed general health check up and their anxiety index was measured by using the Brief Psychiatric Rating Scale (BPRS). The exclusion criteria of this study were: (i) hepatic and/or renal disease, (ii) severe depression, (iii) organic lesion, (iv) uncontrolled diabetic patient.

This study included 33 subjects. Regarding sex, 20 patients were male and 13 were female. While, 26 was religiously Hindus and 7 was Muslims. There were 21 patients (63.6%) who belonged to the age group of 18-35 years, 8 patients (24.2%) belonged to the age group of 36-50 years and only 1 patient was above 50 years. The average age of the subjects was 34.2 years. Regarding occupation there were service holders (12 patients), house wives (7 patients), businessmen (6 patients), students (5 patients) and others (3 patients) including unemployed, retired person etc.

Subjects were formally informed about the study and only those who gave written informed consent were enrolled. The encapsulation contained 500 mg of the plant extract and was administered orally in dose of one capsule twice daily after meal. Hence, each patient ingested two capsules per day. Any concomitant illness and medication during study period were recorded throughout the study. No other anxiolytic medication including β-blockers anti-depressants etc. were permitted throughout the study. The subjects were followed-up at day 30 and finally at day 60 from the starting of medication. They were thoroughly investigated clinically and their anxiety index was noted using questionnaires based on different psychological rating scales. The data were analysed by using Student’s paired t-test and percentile change compared to baseline results.

RESULTS
The results indicated that V. wallichii ingestion significantly attenuated anxiety-stress-disorders (Table-1). The overall clinical features also improved after the treatment.

Before the test drug, V. wallichii therapy, the baseline score of anxiety index was 68.38±8.82, but it declined to 59.38±7.26 (-13.1%) after 30 days and 50.69±6.01 (-25.8%) after 60 days. Further, stress index at baseline was 98.48±8.23. V. wallichii treatment showed significant reduction to 83.47±9.84 (-15.2%, p<0.001) after 30 days and to 76.32±9.26 (-22.5%, p<0.001) on 60 days. On the other hand, depression index also reduced from 56.83±6.92 (at baseline) to 51.19±6.30 (30 days) and 44.97±5.74 (60 days), decline was 9.9% and 20.9% respectively. These results clearly indicated that the test drug, V. wallichii has significant anti-stress and anxiolytic properties. Furthermore, it significantly (p<0.001) improved the willingness of adjustment (20.2%) when it was compared with baseline score. But, the test drug did not alter memory, attention or concentration significantly in the selected subjects.

DISCUSSION
The human society has become complex and, in many ways, more demanding. However, our physiological responses designed to cope with the ever-increasing adverse situations have not evolved appreciably during the past thousand years. The failure of successful adaptation during stressful situations has resulted in stress-related illness that result from, or are associated with, dys-regulation of the stress response. Various attempts have been made to counter the aversive effects of stress, ranging from meditation to anti-stress drugs, particularly the anxiolytic benzodiazepines (BDZ). However, these non pharmacological and pharmacological methods appear to have limited utility. An answer to this perplexing problem of countering stress-induced perturbations of physiological homeostasis came from the plant kingdom. A group of plant-based drugs, the adaptogens, appears to induce a state of nonspecific resistance, enabling the organism to counteract and adapt to various stressors that can adversely affect the physiological system. The topic of adaptogens and their likely utility in stress medicine has been reviewed. Several plants have been shown to have adaptogenic activity, the most prominent being Panax ginseng.

Indian ancient medicinal system, Ayurveda documents several plants, including V. wallichii, which are, categorized as rasayanas. The properties ascribed to rasayanas in Ayurveda are remarkably similar to those of adaptogens. In this study, V. wallichii extract showed overall improvement in stress management. It reduced systolic blood pressure and promoted sleep in general. One of the active ingredient of the test plant is valepotriates. It has sedative action in human. The treatment also helped in mental overwork in daily life. Prolonged treatment of V. wallichii extract showed to inhibit stress in human, without any side effects.
like vertigo, nausea, and dizziness or mental weakness. In a separate study it was noted that valerenic acid, one of the active constituents of this plant, promoted sleep in healthy subjects.22

Further, the present results indicate that, *V. wallichii* has a good efficacy to negate anxiety related disorders in human subjects. Anxiety is a cardinal symptom of many psychiatric disorders and an almost inevitable component of many medicinal and surgical conditions. Symptoms of anxiety commonly associated with dysthmic disorder, panic disorder, agoraphobia, obsessive-compulsive disorder, eating disorder and many personality disorders.13

Generalized stress, particularly if continued in nature, is known to induce melancholic depression. It has been suggested that the symptoms of endogenous depression represent tolerance of the mesocortical system to chronic activation of the stress system.17 Physical changes also occur particularly in severe or melancholic depression: these include insomnia or hypersomnia, anorexia and weight loss (or sometime over eating), decreased energy and libido, and disruption of the normal circadian rhythms of activity, body temperature, and many endocrine functions. Some of (10.0-15.0%) individuals with this disorder display suicidal behavior during their lifetime.23 In that study, it was revealed that, depression index was also reduced after two-month continuous treatment with the test herb, *V. wallichii*. Furthermore, the plant also enhanced the willingness for adjustment in human, but has no role in the betterment of memory, concentration and attention.

The present clinical trial supports the contention that, two-month regular administration with *V. wallichii* reduced stress, attenuated anxiety, negated depression and enhanced adjustment but, could not alter memory, attention and concentration in human. This observations clearly indicate that *V. wallichii* has potential action in the regulation of hypothalamo-hypophyseal-adrenocortical axis (HHA axis) especially, during stress related disorders in human. It appears that *Valeriana wallichii* may be a safer alternative to benzodiazepines for the therapy of stress related clinical disorders.

**ACKNOWLEDGEMENTS**

The authors are grateful to Department of Science & Technology, Govt. of West Bengal, India for providing research grant.

**REFERENCES**


**Table-1:** Role of *Valeriana wallichii* (500mg/twice daily/p.o.) on psychological scoring during Stress Disorders in human

<table>
<thead>
<tr>
<th></th>
<th>Psychological Score (mean ± SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline</td>
</tr>
<tr>
<td></td>
<td>(Day 0)</td>
</tr>
<tr>
<td>Stress</td>
<td>98.48 ± 8.23</td>
</tr>
<tr>
<td>Anxiety</td>
<td>68.38 ± 8.82</td>
</tr>
<tr>
<td>Depression</td>
<td>56.83 ± 6.92</td>
</tr>
<tr>
<td>Adjustment</td>
<td>47.0 ± 6.52</td>
</tr>
<tr>
<td>Memory</td>
<td>3.07 ± 1.32</td>
</tr>
<tr>
<td>Attention</td>
<td>2.53 ± 0.61</td>
</tr>
<tr>
<td>Concentration</td>
<td>2.50 ± 0.73</td>
</tr>
</tbody>
</table>

The results were compared to baseline using student’s paired t-tests. NS= Not significant.